undifferentiated leukemias (25) , lymphatic (7) and primitive cell (7) leukemias, and immature cell erythremias (6 4), the least being the acute monocytic (2), reticulum cell (4) and myeloblastic (4) leukTEmias.
In this series, at the time of writing, we still have 10 patients alive: 7 (6 adults) after six to twelve months, 2 (1 adult) twelve to twenty-eight months, and one nearly twelve years.
Uracil mustard may be only of temporary value in the treatment of patients with acute leukxemia when the leucocyte count is considerably increased; thus 4 such patients, with leucocyte counts of 55,000-176,000, showed rapid reduction in these to normal levels without any clinical improvement on 1-3 mg orally daily for one week. 6-Azauridine: In the sequence of events leading to the de novo biosynthesis of pyrimidine nucleotides, azauridylic acid can interrupt the major pathway by acting as a competitive inhibitor of the enzyme orotodylic decarboxylase, which normally decarboxylates the orotodylic acid to uridylic acid.
The most convenient way of taking advantage of this is to use 6-azauridine which is rapidly converted in the body to azauridylic acid under the influences of uridine kinase.
6-azauridine is a potent inhibitor of animal tumours and has some effect on human tumours. It has therefore been tried out on patients with acute leukemia. 6-azauridine is extremely difficult to prepare in a pure form, which is essential, and so far has only been available in quantities sufficient to try it out on some 15 cases -13 having acute leukwemia.
The dosage used has been 10-20 g daily for periods of twenty-one days given as a continuous intravenous dripthroughoutthetwenty-fourhours. Pure 6-azauridine is remarkably free from toxic effects of any kinds, but produces a very rapid fall in the total white cell count showing a preferential effect on blast cells. It has produced dramatic effects in resolving leukxemic infiltration of the skin, reducing enlarged lymph nodes and spleen, and in most patients it hasproduced rapid subjective improvement.
Since it is a potent inhibitor of nucleic acid synthesis, gross chromosomal changes may be produced (Elves et al. 1963) .
The inconvenience of continuous intravenous therapy can be obviated by the use of the triacetyl derivative which works in the same manner when given in doses of 7 5-10 g orally.
The most striking results are the preferential effects on the blast cells which were diminished dramatically in all the 13 acute leukemias Myelomatosis is not a common disease and it would be a mistake to overestimate the importance of the problem of its treatment, especially with chemotherapy, in relation to that of leukemia and certain other malignant reticuloses. In Edinburgh, it has been possible to study the records of over 200 cases seen over a periodof twenty-five years, and in recent years when there has been an increasing diagnostic awareness of the disorder, about 15 new cases are referred each year to the Department of Radiotherapy which serves a population of approximately 1* million. It would seem, therefore, that there must be few clinicians who are in a position to conduct more than very limited trials with chemotherapeutic agents in myelomatosis and who are able to assess the results against an adequate background experience of the natural history of the disease and the results obtained over the years with the longaccepted treatment by radiotherapy. The opportunity to do so affords little reason to feel satisfied with the progress made in the treatment of myelomatosis with any of the chemotherapeutic agents at present available.
A study of a large number of cases of myelomatosis (Innes & Newall 1961) shows that there are broadly four main types of clinical presentation: (1) Solitary myeloma, with local bone tumour. (2) Multiple myeloma, with multiple bone tumours and anemia. (3) Diffuse myelomatosis characterized by widespread marrow involvement and progressive antmia, without tumour formation. (4) The rare extramedullary plasmacytoma in which extramedullary tumours are the main feature. All types are, of course, only differing aspects of a single pathological process and tend to merge as the disease advances. From the point of view of treatment, two main considerations arise from accepting such a working classification. The first is that skeletal lesions causing severe bone pain call for localized irradiation which is the one proven method of treatment to secure early relief of symptoms. In the event of dramatic vertebral collapse resulting in paraplegia, surgery followed by irradiation is necessary. The second point is that the survival rate of patients varies considerably with the clinical type of the disease when first diagnosed, ranging from a 14% five-year survival rate in the solitary myeloma cases, to a 5 % three-year rate in patients with multiple myeloma and with the poorest prognosis in the cases of diffuse myelomatosis presenting with anemia.
Since localized irradiation is the most certain method of achieving relief of local symptoms, chemotherapy when used is employed as an adjunct to irradiation in an attempt to retard the progression of the disease, or is given alone for the same reason in the already widespread state of the condition where there is no local source of symptoms that demands X-ray palliation. This rational approach to the problem of what is best for the patient makes it difficult to assess the independent effects ofchemotherapy and localized irradiation, since drugs are used mainly in cases where the disease process has already become widespread and the outlook for survival correspondingly poor.
Another difficulty in assessing chemotherapy in myelomatosis is to define the criteria of improvement which can be accepted as evidence of beneficial effect. Relief of bone pain, correction of anamia and abnormal serum protein pattern, a fall in raised E.S.R. and disappearance of Bence Jones proteinuria, are all possible yardsticks of improvement, but these are by no means constant initial features of many of the cases that are started on treatment. Radiographic evidence of the healing of a destructive skeletal lesion is perhaps the only definite evidence of local regression of the disease. Such, however, takes a considerable time to occur and though it is seen frequently after localized irradiation, it has so far never been regularly achieved after the use of any chemotherapeutic agent.
Urethane was the first chemotherapeutic drug to be ascribed any success in the treatment of myelomatosis. Since Loge & Rundles reported its use in 1949, many workers have confirmed its palliative value in the disease, and after fourteen years it remains the drug most recommended in current textbooks of hematology. It seems doubtful if the exact mode of action of this simple compound is yet understood. In the recommended doses it is nauseating to the patient, however administered, producing at best only palliative relief with occasional improvement in anemia and no evidence of healing in destructive bony lesions. It is perhaps the most interesting chemotherapeutic agent in myelomatosis, and though it is quiteclearly not the answer, it is possible that further studies of its mode of action might prove more rewarding than has been the case with many of the more complex agents that have for fleeting periods been claimed to be superior.
In view of the known beneficial effects of localized irradiation in myelomatosis, it would seem logical to expect that radiomimetic drugs such as the nitrogen mustards might be helpful in checking the widespread proliferation of abnormal plasma cells in this disease. The obvious drawback to their use in high dosage is that they inevitably produce severe bone marrow depression. This is unjustifiable in early cases of myelomatosis where the bulk of the marrow is as yet unaffected by the disease and where localized lesions can and should be controlled by radiotherapy; and in later cases where the disease itself has already reduced marrow function, intensive chemotherapy is likely to add to the hazards of pancytopenia. Nevertheless, several types of nitrogen mustard have been tried in myelomatosis ranging from the early oral compounds prepared by the Chester Beatty Institute to the recent variations such as cyclophosphamide and melphalan. The fact that so many of these and other agents have from time to time been used in recent years is itself sufficient indication that none is of proven value. All alkylating agents can produce severe thrombocytopeniato which patients with diffuse myelomatosis are very proneand some have produced other undesirable side-effects such as the alopecia resulting from cyclophosphamide which can be a most distressing complication for the patient.
During the past nine years in Edinburgh, patients with myelomatosis in whom chemo-therapy seemed indicated have been treated with a combination of urethane and an oral nitrogen mustard (Innes & Rider 1955) . Capsules containing 0 5 g urethane and 25 mg of the Chester Beatty oral mustard R151 are administered after meals in a dose of 2-4 capsules daily. The ideas behind this combination were that it would permit long-term maintenance treatment with the dosage of each drug being small enough to minimize gastro-intestinal side-effects and rapid bone marrow depression and that it might possibly result in some additive effect of two compounds with differing modes of action.
In attempting to assess the value of this chemotherapy in the 84 patients treated full allowance has had to be made for the fact that 61 of them had on one or more occasions received localized irradiation for the relief of local symptoms. As already stated, positive criteria of improvement in, this disease are difficult to define, and in many cases there remained an element of doubt as to whether the temporary improvement noted was due to the drugs, to irradiation, or to variations in the natural progress of the condition. With these reservations, the results in this group of patients can be summarized in Table 1 . given during irradiation induced remission * Only 6 cases with objective signs ofregression of disease While taking this combined chemotherapy, nausea and gastric upset occurred in 13 patients, necessitating reduction in dosage, and evidence of hemopoietic depression in 20 patients was believed to be related to the treatment. The higher dosage of four capsules daily (2 g urethane and 100 mg R151) used early in the series has been replaced by half of this dose employed both as initial and maintenance dosage in recent years.
The overall results of this chemotherapeutic trial do little to suggest that the drugs used are other than of very limited value in the management of cases of myelomatosis. While it is felt that clinical remission was attributable to their administration in 17 % of the patients treated, there was little tangible evidence that the progress of the disease was arrested or even delayed in any case by their action. There would in fact appear to be little justification for the use of any systemic agent capable of damaging the bone marrow in patients whosemarrow was not alreadyextensivelyinvolved in the hope of delaying the progress of the disease.
The trial of urethane and R151 has been continued in a number of patients, and for a period of time sufficient to permit an adequate assessment of this form of treatment. As new chemotherapeutic agents become available, there is a tendency for clinicians dissatisfied with current drugs to change to the more recent preparations in the hope of better results. In a comparatively rare disease, such frequent changes may well render it impossible to obtain a satisfactory assessment of any one drug or group of agents, and this may well be the case in the instance of the nitrogen mustards of which several more recent forms than Rl 51 have appeared in the last few years. In addition to those treated with urethane and R151 small numbers of patients with myelomatosis in Edinburgh have been given other forms of chemotherapy, such as cyclophosphamide, a combination of cyclophosphamide and urethane, and vinblastine. The results have so far proved no more impressive than those with urethane and R151. It is significant reflection on the overall value of chemotherapy in this disease that in Edinburgh the length of survival of 120 patients treated by all forms of therapy since 1954 has remained essentially unchanged as compared with that of the 85 patients treated with irradiation alone before 1954.
A study of myelomatosis in all its many fascinating aspects would seem to suggest that its natural progress may be very variable and that from the time of diagnosis about one-sixth of the patients may experience temporary remissions which can sometimes appear attributable to whatever form of treatment is being employed. The first truly successful chemotherapeutic agent to be introduced will surely very soon declare its value in achieving a dramatic improvement in this picture.
